Optimise Your RWE Investments through a Platform Based Approach

19th September, 2017
Time: 13:00 - 14:00

Location: Webinar
Timezone: (GMT -5:00) Eastern Time (US & Canada), Bogota, Lima

With the increasing drug development cost, shift from volume to value-based pricing, and competition from generics and biosimilars, pharma and life science organizations are looking towards real world evidence (RWE) to prove the value – cost, safety, and effectiveness of their medicinal products.

However, the current real-world data comes in structured and unstructured format, in various data standards, and is laden with varied data quality issues. The industry is looking to define a platform-based approach to address the functional and technical complexities of RWE and harness the real-world datasets across the pharma value chain.

Key Insights

  • Understand the key business use cases and stakeholders of RWE
  • Gather an industry perspective on RWE and its impact on entire pharma value chain
  • Learn the current challenges and the need for a platform based approach
  • Understand the current state of RWE analytics implementation and associated complexity
  • Understand RWE business problem with respect to observational research
  • Get an overview of a platform-based approach to harness real-world datasets for observational research


Jim Carroll, MBA
Vice President, Real World Evidence, Commercialisation & Outcomes, ICON

Jeffrey Springer
Vice President, CitiusTech, Inc.

Kristi Jones
Director of Product Management
CitiusTech, Inc.

Target Audience

This webinar is intended for pharmaceutical professionals working in:

  • Real world evidence
  • Health economics and observational research
  • Epidemiology
  • Late stage development

Complete the form today to view the archived recording, originally broadcast on September 19, 2017 in collaboration with DIA and CitiusTech, Inc.